Startseite Medical and Economic Outcomes of Point-of-Care Testing
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Medical and Economic Outcomes of Point-of-Care Testing

  • Christopher P. Price
Veröffentlicht/Copyright: 1. Juni 2005
Veröffentlichen auch Sie bei De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Band 40 Heft 3

Abstract

Point-of-care testing is concerned with the immediacy of response, primarily because of the need to act in a life-threatening crisis or to provide counsel in the ongoing management of a chronic disease. There are both clinical, operational and economic benefits that can accrue from this testing modality which may be observed from several perspectives – the patient, the clinician, the healthcare provider, the healthcare purchaser and society. Thus point-of-care testing can improve the management of chronic diseases such as diabetes, compromised coagulation status and epilepsy – both in terms of optimisation of, and compliance with, therapy. There are also life-threatening crises that can be averted by rapid provision of test results. Each of these scenarios can lead to more efficient use of healthcare resources.

:
Published Online: 2005-06-01
Published in Print: 2002-04-10

Copyright © 2002 by Walter de Gruyter GmbH & Co. KG

Artikel in diesem Heft

  1. New Developments in Clinical Chemistry and Laboratory Medicine as Documented by EUROMEDLAB 2001 the 14th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine, Prague, May 2631, 2001
  2. Haptoglobin Polymorphism and Body Iron Stores
  3. Immunohistochemistry in the Evaluation of Spermatogenesis and Sertoli Cell's Maturation Status
  4. Study of Therapy Resistance in Cancer Cells with Functional Proteome Analysis
  5. Proposition of an Aging Indicator from General Health Examination in France
  6. Comparison of Plasma Cardiac Troponins T and I in Chronically Hemodialyzed Patients in Relation to Cardiac Status and Age
  7. Medical and Economic Outcomes of Point-of-Care Testing
  8. Are Laboratory Investigations Recommended in Current Medical Practice Guidelines Supported by Available Evidence?
  9. New Aspects on Angiotensin-Converting Enzyme: from Gene to Disease
  10. Oxypurines, Protein, Glucose and the Functional State of Blood Vasculature Are Markers of Renal Calcium Stone-forming Processes? Observations in Men with Idiopathic Recurrent Calcium Urolithiasis
  11. Long-Chain Polyunsaturated Fatty Acids in Rat Maternal Milk, Offspring Brain and Peripheral Tissues in Essential Fatty Acid Deficiency
  12. Simultaneous Quantification of Sirolimus, Everolimus, Tacrolimus and Cyclosporine by Liquid Chromatography-Mass Spectrometry (LC-MS)
  13. Pancreatic Phospholipase A2 Activity in Acute Pancreatitis: a Prognostic Marker for Early Identification of Patients at Risk
  14. Serum Cytokeratin Fragment 21.1 (CYFRA 21.1) as Tumour Marker for Breast Cancer: Comparison with Carbohydrate Antigen 15.3 (CA 15.3) and Carcinoembryonic Antigen (CEA)
  15. Serum Cholesterol Levels in Neutropenic Patients with Fever
  16. Evaluation of Two Mg2+-Selective Electrodes by Means of a Flow-Through Device
  17. The Management of Clinical Laboratories in Europe: a FESCC Survey
  18. Meetings and Awards
Heruntergeladen am 19.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2002.040/html?lang=de
Button zum nach oben scrollen